Astellas Pharma Inc.("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) announced that Astellas today established a new active pharmaceutical ingredient (API) manufacturing subsidiary "Astellas Pharma Chemicals Co., Ltd." through a company split.
Astellas separated its Takahagi Plant, the manufacturing and analytical function for APIs for investigational use at the Process Chemistry Labs. and the site management function of the Bulk Technology Administration and transferd to Astellas Pharma Chemicals Co., Ltd.
The new subsidiary has through function for the production of APIs for investigational use and finished products and will contribute to the timely and accurate supply of APIs for investigational use, early establishment of new product production, the stable supply of products and the improvement of API manufacturing technology of the Astellas group.
The details of the new subsidiary are as follows:
||Astellas Pharma Chemicals Co., Ltd.
||160-2, Akahama, Takahagi city, Ibaraki Prefecture
||Motoyoshi Katano, President
||100 million yen
|Number of employees
||April 3, 2006
||Production and marketing of drugs and other products